189 Treatment of chronic hepatitis C with peginterferon ALFA-2A (40KD) (PEGASYS®) and ribavirin (COPEGUS®): patient age has a marked influence on the individual estimated probability of achieving a sustained virological response

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 38; p. 246
Main Authors Foster, Graham R., Fried, Micheal W., Hadziyannis, Stephanos J., Chaneac, Monique
Format Journal Article
LanguageEnglish
Published Elsevier Inc 2003
Online AccessGet full text

Cover

More Information
ISSN:0270-9139
1527-3350
DOI:10.1016/S0270-9139(03)80232-X